KR20090027383A - Composition for preventing or treating hyperlipidemia - Google Patents

Abstract

A composition of preventing or treating excellently hyperlipidemia is provided to have low toxicity or side effect though the composition is used for a long time. A composition of preventing or treating hyperlipidemia includes angelica keiskei and Curcumae longae Rhizoma as active component at a weight ratio of 10:1 - 1:10. The angelica keiskei and Curcumae longae Rhizoma are independently crushed material of crude drug itself, the dry pulverized material of the crude drug or extracts of solvent. The extract of the solvent is extract of solvent selected from a group consisting of water, C1-C4 alcohol, ethylacetate and a mixture thereof.

Description

Composition for preventing or treating hyperlipidemia

The present invention relates to a composition for the prevention or treatment of hyperlipidemia, and more particularly to a composition for the prevention or treatment of hyperlipidemia comprising a plant herbal as an active ingredient.

Hyperlipidemia refers to a condition where the amount of fat in the blood is higher than normal. Too much fat in the blood deposits a mass of fat on the walls of blood vessels, and over time the fat mass causes a condition called atherosclerosis, which narrows the inner diameter of the arteries and blocks blood flow. This causes stenosis in the coronary artery, an artery that supplies blood to the heart muscle, and the heart fails to receive enough oxygen and nutrients, resulting in coronary artery disease such as angina pectoris or myocardial infarction, and ischemic stroke when blood flow to the brain decreases. Induced, less blood flow to the lower limbs caused necrosis of the limbs due to lack of blood supply. These hyperlipidemia can be classified into hypercholesterolemia, hypertriglyceridemia, low density lipoprotein cholesterolemia and the like.

The cardiovascular disease caused by the hyperlipidemia is the leading cause of death in Korea, which continues to increase due to lack of exercise, stress, and eating out of modern people. The average blood cholesterol level in Koreans was 60s (139-166mg / dl), 70s (154-189mg / dl), 80s (175mg / dl), 90s (184mg / dl), 2000s (203mg / dl) This is increasing year by year, similar to the increase in the incidence of cardiovascular disease.

Many drugs have been developed to treat hyperlipidemia. Among them, many studies have been conducted on HMG-CoA reductase inhibitors (eg simvastatin, lovastatin, atorvastatin) which are cholesterol rate regulating enzymes. HMG-CoA reductase inhibitors are also known to be effective in lowering blood cholesterol by inducing LDL receptor mRNA expression. In addition, PPAR alpha agonists, fibrate-based (e.g., clofibrate, fenofibrate), which bind bile acids in the intestine and inhibit the recycling of bile acids to the intestine, thereby facilitating excretion of bile acids into feces ( E.g., cholestyramine, and ACAT (Acyl-CoA: cholesteryl Acyltransferase) inhibitors (e.g. ezetimibe, Abashimibe), and enzymes necessary for the digestion and absorption of intestinal lipids, CETP inhibitors that increase HDL by inhibiting the conversion of high density lipoprotein (HDL) to low density lipoprotein (LDL).

Among the drugs for treating hyperlipidemia, HMG-CoA reductase inhibitors may cause side effects such as hepatotoxicity, indigestion and abdominal pain, and other mechanisms of drugs may also cause side effects such as nausea and indigestion. In addition, it can be a problem in the treatment of hyperlipidemia, which should be managed by steadily administering drugs in the long term.

Therefore, there is an urgent need for the discovery of drugs that have an excellent effect on the prevention and treatment of hyperlipidemia and can significantly lower the possibility of toxicity or side effects even when taken for a long time.

On the other hand, Angelica keiskei Koidzumi is a perennial plant of the Araaceae family and is also known as Sinseoncho, Seonsamcho, and Sinchocho. Myeongilyeop is mainly grown in subtropical regions, and in Korea in 1970s, it is widely used as food such as green juice in Korea. In addition, Myeongilyeop has been used as a folk remedy for the treatment of hypertension, liver disease, neuralgia, etc., and physiological activities such as antihyperlipidemia, lowering blood pressure, anticancer action, gastric acid secretion are reported.

According to previous studies on the antihyperlipidemic effect of Myeongil-yeop, xanthoangelol, a major chalcone component of Myeongil-yeop, reduced cholesterol and triglycerides in serum LDL and liver (Ogawa H. et al, Beneficial effect of xanthoangelol, a chalcone compound from Angelica keiskei, on lipid metabolism in stroke-prone spontaneously hypertensive rats, Clinical and Experimental Pharmacology and Physiology, 34, pp. 238-243, 2007), another Calcium component, 4-hydroxyderricin, reduces serum VLDL and neutral lipids in the liver. (Ogawa H. et al, Hypotensive and lipid regulatory actions of 4-hydroxyderricin, a chalone from Angelica keiskei, in stroke-prone spontaneously hypertensive rats, Clinical and Experimental Pharmacology and Physiology, 32, pp. 19-23 2005) . In addition, Cynaroside (loteolin-7-O-β-glucoside), a major flavonoid glycoside, has been reported to lower triglyceride and cholesterol in the blood. [Park Jung-ro et al., Effects of Angelica keiskei on Lipid Metabolism in Rats, Korean Food Korean Journal of Nutrition Science, 26, pp. 308-313, 1997].

Meanwhile, Curcumae Rhizoma refers to the root of Curcuma longa, which grows and grows in Southeast Asia, including India and Okinawa, and is a medicinal plant grown in the South Central region of Korea. It is said that it is effective. Curcumin, a representative component of turmeric, is known to be effective in improving hyperlipidemia and reducing cholesterol concentration by promoting bile secretion in hyperlipidemia models.

Previous studies on the improvement of hyperlipidemia of curcumin, the main active ingredient of turmeric, have shown that oral administration of curcumin to atherosclerosis-induced rabbits significantly reduces total cholesterol, triglycerides, and LDL levels (MC). Ramirez-Tortosa et al., Oral administration of turmeric extract inhibit LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis, Atherosclerosis, 147, pp 371-378, 1999), oral administration of curcumin to rats with hypercholesterolemia Cholesterol and LDL levels have been reported to be significantly reduced (Hossam MM et al., Curcumin attenuates diet-induced hypercholesterolemia in rats, Med Sci Monit, 11, pp228-234, 2005).

Accordingly, the present inventors have completed the present invention as a result of trying to find a plant herbal medicine having an excellent effect on the prevention and treatment of hyperlipidemia but having low toxicity or side effects even when taken for a long time.

Accordingly, it is an object of the present invention to provide a composition derived from a plant herbal medicine having an excellent prevention and treatment effect of hyperlipidemia.

Another object of the present invention to provide a composition for the prevention of limb necrosis due to atherosclerosis, coronary artery disease, ischemic stroke, or lack of blood supply.

Still another object of the present invention is to provide a medicine comprising the composition.

Another object of the present invention to provide a dietary supplement comprising the composition.

In order to achieve the above object, the present invention provides a composition for the prevention or treatment of hyperlipidemia, which comprises Munifolium and turmeric as active ingredients.

In another aspect, the present invention provides a composition for the prevention of limb necrosis due to atherosclerosis, coronary artery disease, ischemic stroke, or lack of blood supply, which comprises Mt.

The present invention also provides a medicine comprising the composition.

In addition, the present invention provides a health supplement comprising the composition.

Hereinafter, the present invention will be described in more detail.

The present inventors conducted research on various plant herbs to find plant herbs that are effective in the prevention and treatment of hyperlipidemia. As a result, the present inventors found that the composition containing both sunday and turmeric as active ingredients in lowering the concentration of triglyceride, total cholesterol, and low density lipoprotein in the blood compared to the case of administering sunday and turmeric alone, respectively. It has been found to have a positive effect. In addition, in terms of increasing the concentration of high-density lipoprotein called good cholesterol, it was found that the composition containing both sunday and turmeric exhibits a synergistic effect compared to the case of administering sunday and urine alone.

Therefore, in one aspect, the present invention provides a composition for the prevention or treatment of hyperlipidemia, which comprises bright leaf and turmeric as active ingredients. The hyperlipidemia specifically includes, but is not limited to, hypercholesterolemia, hypertriglyceridemia, or low density lipoprotein cholesterol. The composition for preventing or treating hyperlipidemia is due to the prevention or treatment of hyperlipidemia, atherosclerosis caused by hyperlipidemia, coronary artery disease (eg angina pectoris, myocardial infarction), ischemic stroke, or limbs due to insufficient supply of blood. It is effective in preventing necrosis.

Thus, in another aspect, the present invention provides a composition for the prevention of limb necrosis due to atherosclerosis, coronary artery disease, ischemic stroke, or lack of blood supply, which comprises Munifolium and turmeric as active ingredients.

The mixed ratio between the bright leaf and the turmeric is preferably 10: 1 to 1:10 by weight, and may include 2: 1 to 1: 2 parts by weight.

Bright leaf and turmeric, which are components of the composition of the present invention, may be included in the form of an extract obtained by a conventional extraction method known in the art, or may be included as a ground powder of the herbal medicine or a dry ground powder of the herbal medicine.

The extract of the bright leaf or turmeric obtained by the conventional extraction method may be an extract of a solvent selected from the group consisting of water, C ₁ -C ₄ alcohol, ethyl acetate, and combinations thereof. The extract of Sunnyleaf and Curcuma may be preferably an extract of C ₁ -C ₄ alcohol, more preferably an extract of ethanol, and more preferably an extract of 70 to 100% ethanol. When extracted with a solvent, the extraction temperature may be carried out at room temperature, but for more efficient extraction can be carried out under warm conditions, preferably at a temperature of 40 to 80 ℃. Extraction time may be carried out for 72 hours or more when extracted to room temperature, 5 to 24 hours under warm conditions.

The extract extracted by the method as described above may be used as it is, but may be used in the form of concentrated X, or may be concentrated and then lyophilized to be used as a lyophilized form. Preferably, it is used in concentrated form so that it can be used at a sufficient concentration.

The composition for preventing or treating hyperlipidemia according to the present invention can be used for the prevention or treatment of hyperlipidemia, specifically for the prevention or treatment of hypercholesterolemia, hypertriglyceridemia, or low high density lipoprotein cholesterolemia. It is demonstrated in the examples below that the compositions according to the invention are effective in hyperlipidemia. Specifically, as a result of administering the composite composition of the extract of Myeongilyeop and Turmeric extract according to one embodiment of the present invention to SD rats induced with hypertriglyceridemia and SD rats induced with hypercholesterolemia, Neutral fat, total cholesterol, and LDL in terms of lowering the synergistic effect compared to the case of administration of the extract of the bright leaf or turmeric respectively. In addition, in terms of the increase in the concentration of HDL which is a good cholesterol, the composite composition of the extract of Myeongil-yeop and the extract of Turmeric showed a synergistic effect compared to the case of administration of the extract of Myeongil-yeop or the extract of Turmeric, respectively.

In addition, the composition according to the present invention can be used for the prevention or treatment of various diseases known in the art that can be caused by hyperlipidemia due to the prevention or treatment effect of hyperlipidemia. Such diseases include, but are not limited to, atherosclerosis, coronary artery disease (eg, angina pectoris, myocardial infarction), ischemic stroke, necrosis of the limbs due to lack of blood supply, and the like.

Preventive or therapeutic composition for hyperlipidemia, which comprises Myeongil Leaf and Turmeric according to the present invention as active ingredients, atherosclerosis, coronary artery disease (angina, myocardial infarction), ischemic stroke, or prevention of limb necrosis due to insufficient supply of blood The composition for use can be used as a raw material of medicines that are effective in the treatment or prevention of each disease.

Thus, in another aspect, the present invention provides a medicament comprising the composition according to the present invention, and a pharmaceutically acceptable carrier or additive.

The medicament may be formulated in conventional pharmaceutical formulations known in the art. The medicament may be formulated and administered in any dosage form including, but not limited to, oral, injectable, suppository, transdermal, and non-administrative agents, but preferably liquids, suspensions, powders, granules, It may be formulated into a formulation for oral administration such as tablets, capsules, pills, or excipients.

When formulated into each of the above formulations, it may be prepared by the addition of a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation. Representatively, when formulated into a dosage form for oral administration, one or more of a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative may be used as the carrier, and as an additive, flavors, vitamins, and antioxidants may be used. One or more types can be selected and used out of them.

The carrier and the additive may be any pharmaceutically acceptable, and specifically, a diluent may include lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and a lubricant may include magnesium stearate or talc, and a binder may be polyvinylpyrrolidone. Or hydroxypropyl cellulose is preferred. In addition, as a disintegrant, calcium carboxymethyl cellulose, sodium starch glycolate, potassium polyacrylic acid, or crospovidone, sweetener as white sugar, fructose, sorbitol, or aspartame, stabilizer as carboxymethyl cellulose sodium, beta-cyclodextrin, As lead, or xanthan gum, and preservative, methyl paraoxybenzoate, propyl paraoxybenzoate, or potassium sorbate is preferable.

In addition to the above ingredients, in order to enhance the taste as a known additive, natural flavors such as plum flavor, lemon flavor, pineapple flavor, herbal flavor, natural pigments such as natural fruit juice, chlorophyllin, flavonoid, fructose, honey, sugar alcohol, sugar Sweetening ingredients such as, or may be used by mixing an acidulant such as citric acid, sodium citrate.

In order to obtain a prophylactic or therapeutic effect of each of the above diseases including hyperlipidemia, the medicine has a total daily dosage of 8-50 mg as an extract and 40-250 mg as a herbal medicine, based on an adult 60 kg body weight as an active ingredient. It may be administered orally, optionally divided several times.

In addition, the composition for the prevention or treatment of hyperlipidemia comprising myeongyip and turmeric according to the present invention as active ingredients, atherosclerosis, coronary artery disease (angina, myocardial infarction), ischemic stroke, or limb necrosis due to insufficient supply of blood Prophylactic composition of may be used as a raw material of dietary supplements that are effective in the treatment or prevention of each disease.

Therefore, in another aspect, the present invention provides a dietary supplement comprising the composition according to the present invention and a food acceptable carrier or additive.

Such dietary supplements may be formulated in the form of conventional dietary supplements known in the art. The dietary supplement may be prepared, for example, as a powder, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, extracts, teas, jelly, extracts, or beverages. As the food acceptable carrier or additive, any carrier or additive known to be usable in the art may be used to prepare a formulation to be prepared. The health supplement food of the present invention processed in various forms as described above can be used for the prevention or treatment of hyperlipidemia and the prevention of various diseases caused by hyperlipidemia with little side effects to the human body, and is easy to take and usefully. Can be used.

The medicine and health supplement according to the present invention may be administered at the same time to the day and day turmeric containing the active ingredient, but at a predetermined interval within a range that can exhibit the synergistic pharmacological activity of the day and green grass It may be administered sequentially. If the active ingredient of light and turmeric is to be administered at predetermined intervals, each active ingredient may be formulated in a separate, separate formulation. If you want to simultaneously administer the active ingredients of Sunilyeon and turmeric may be formulated in a uniformly mixed form in one formulation, it may be formulated in a separate formulation and then administered at the same time.

As described above, the composition according to the present invention includes both bright leaf and turmeric, and thus has a prophylactic and therapeutic effect of synergistic hyperlipidemia, compared to the case of using each of them separately. By using the raw herbal medicine as a raw material, there is an advantage that can solve various side effects that the conventional hyperlipidemia treatment agent had.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for the understanding of the present invention, and the scope of the present invention is not limited by them in any sense.

Example 1

Preparation of Sunil Leaf Extract

Myeongilyeop was purchased from a farm in Yangju, Korea in July 2006, and used to dry at 80 ℃. 500 g of dayleaf powder was refluxed at 4 ° C. with 4 L of 90% ethanol for 4 hours, and then concentrated under reduced pressure to obtain 110 g of concentrate.

Example 2

Preparation of Turmeric Extract

Turmeric was purchased as a dry powder at Kyungdong Market in September 2006. 1 kg of turmeric powder was refluxed for 4 hours at 60 ° C. with 3 L of 90% ethanol and concentrated under reduced pressure to obtain a concentrate of 130 g.

Example 3

Preparation of the composite composition of light leaf and turmeric

Myeongil leaf extract and turmeric extract prepared in Examples 1 and 2 were mixed in a weight ratio of 1: 1 to prepare a composite composition.

Experimental Example 1

Effect of Complex Composition on Triglyceride Concentration in Blood

1. Induce hypertriglyceridemia and administration of test substance

Poloxamer 407 (500x / kg) was intraperitoneally administered to Sprague-Dawley female Rats (160-180g) and divided into 8 groups of 8 rats to induce hyperlipidemia in all groups except the normal group. . Poloxamer 407 is a hydrophilic copolymer that is involved in HMG-CoA reductase activity during the intraperitoneal administration of the body, thereby rapidly raising the neutral lipid in the blood (Thosmas P et al., Mechanism of Poloxamer 407-Induced Hypertriglyceridemia In The Rat, Biochemical Pharmacology, 46, pp 1037-1042, 1993). Therefore, rats that induced hypertriglyceridemia with poloxamer 407 were evaluated to evaluate the effect of triglyceride reduction in blood.

The poloxamer 407 intraperitoneal administration was done once every three days, and from the second day after the first poloxamer 407 intraperitoneal administration, the negative control vehicle (Tween80 1%, CMC 0.5% in saline) and the positive control vehicle were simvastatin 50 mg / kg. CMC 1%) was administered, and the extract of Myeongil Leaf, turmeric extract and the composite composition prepared in Examples 1 to 3 were dissolved in vehicle (Tween80 1%, CMC 0.5% in saline) at 500 mg / kg for 3 weeks, respectively. After oral administration, blood fat levels were measured. The significance test between the five test groups was ANOVA test followed by Duncan's multiple test at the α = 0.05 level. The significance between the negative control group and the experimental group was verified at the p <0.05 level using the student t-test.

2. Comparison of serum triglyceride levels

The measurement result of the triglyceride concentration in blood is shown in Table 1 below.

TABLE 1

As shown in Table 1, when the complex composition of the present invention was administered for 15 days, it was confirmed that the serum triglyceride concentration was significantly lower than the negative control (p <0.05).

In addition, the concentration of triglyceride in the blood was decreased by 12.7% compared to the negative control group in the Myeongil leaf extract alone group, 29.4% in the turmeric extract alone group compared to the negative control group, but in the group of the composite composition administration group 57.9 compared to the negative control group It showed a reduction effect of%. Therefore, it was confirmed that synergistic effect was shown in the effect of reducing triglyceride concentration in the blood when administered in the combined regimen than in the case of daily and turmeric respectively.

Experimental Example 2

Effect of Complex Composition on Total Cholesterol Concentration in Blood

1. Hyperlipidemic induction and oral administration conditions

Sprague-Dawley female rats (160-180g) were divided into six groups of seven per group, and fed a high-fat diet (containing 8% by weight of fat and 1% by weight of cholesterol) for eight weeks in the remaining groups except the normal group. The hyperlipidemia model was set. The experimental diet basically followed the AIN-76 pattern and used as a source of fat for lard (Lard) and cholesterol from Sigma. The temperature of the feeding room was 22 ㅁ 2 ℃, relative humidity 65 ㅁ 5%, the contrast was adjusted in 12 hour cycle. Experimental diet and drinking water were freely consumed.

After 8 weeks of hyperlipidemic diet, the negative control group received the medium (1% solution of Tween80 and 0.5% CMC in saline) and the positive control group received the medium (1% aqueous solution of CMC in saline) at a dose of 50 mg / kg simvastatin. It was dissolved and administered, and the extract of Myeongyipyeon extract, turmeric extract, and complex composition prepared in Examples 1 to 3 were dissolved in a medium (Tween80 1% and CMC 0.5% aqueous solution in saline) at a dosage of 500 mg / kg, respectively, for 3 weeks. After oral administration, the concentrations of total cholesterol, LDL, and HDL in blood were measured.

2. Comparison of Serum Total Cholesterol, LDL and HDL Levels

The results of measuring the concentration of total cholesterol, HDL, and LDL in blood are shown in Table 2 below. In addition, the result is shown as a bar graph in FIG.

As shown in Table 2 and Figure 1, the concentration of total cholesterol in blood was significantly reduced compared to the negative control group when the composite composition was administered (p <0.05).

In addition, the concentration of total cholesterol in blood was decreased by 22.1% and 28.6%, respectively, compared to the negative control group in the daylight extract alone administration group and the turmeric extract alone administration, but 42.2% decrease in the combination composition administration group. Therefore, it was confirmed that synergistic effect was observed in the effect of lowering blood cholesterol concentration when administered in a composite composition than when administered the extract of Tulip and Curcuma chinensis.

Blood HDL is an important factor that lowers the risk of atherosclerosis by playing a role in transferring the synthesized cholesterol and surplus cholesterol of blood vessels to the liver. The blood HDL was significantly increased (p <0.05) compared to the negative control group when the composite composition of the extract of Myeongil-yeop and Turmeric extract was administered. In addition, the HDL concentration of the extract of the composite composition administration group was higher than that of the monocotyledon extract alone and turmeric extract alone administration group. Therefore, in terms of the effect of HDL synergy in the blood, it was confirmed that the composite composition of the extract of Myeongilyeon and Turmeric extract shows a synergistic effect compared with the case of administration alone.

LDL in the blood is the most susceptible to oxidation of lipoproteins, and oxidized LDL is a factor that promotes atherosclerosis by toxic cells. The blood HDL was significantly decreased (p <0.01) compared to the negative control group when the composite composition of the extract of Myeongyipyeon and Curcuma extract was administered. In addition, the concentration of LDL in the group administered with the extract alone and the extract treated with the turmeric extract alone was lower. Thus, in terms of the blood LDL lowering effect, it was confirmed that the composite composition of Sunilyeon extract and turmeric extract show a synergistic effect compared with the case of administration alone.

In addition, AI (Atherogenic Index) refers to the value of (Total Cholesterol-HDL Cholesterol) / HDL-Cholesterol, and these AIs and Total Serum Cholesterol (TC) / LDL, and LDL / HDL are known to reduce the risk of atherosclerosis. That is an index. The AI, TC / LDL, and LDL / HDL were significantly reduced compared to the negative control group when the composite composition of day leaf extract and turmeric extract was administered. In addition, AI, TC / LDL, and LDL / HDL were lower in the composite composition administration group of the extract than that of the day leaf extract alone and turmeric extract alone administration group. Therefore, in terms of the effect of reducing the risk of atherosclerosis, it was confirmed that the composite composition of the perennial extract and the turmeric extract show a synergistic effect compared with the case of administration alone.

As a result, the composite composition of the extract of Myeongilyeop and Turmeric extract not only shows synergistic effects on blood triglyceride reduction and total cholesterol reduction, but also on HDL synergistic effect and LDL reduction compared to the administration alone. Since it has been confirmed that there is a synergistic effect on the effect, it can be expected not only to exhibit an excellent effect on the prevention and treatment of hyperlipidemia, but also to have an excellent effect on prevention of various diseases caused by hyperlipidemia.

1 is compared with a negative control, a positive control group, Myeongilyeop extract, and turmeric extract on the effect of the complex composition according to one embodiment of the present invention on serum cholesterol concentration in hyperlipidemia-induced rats It is a graph showing the results.

Claims (12)

A composition for preventing or treating hyperlipidemia comprising Angelica keiskei Koidzumi and Curcumae Rhizoma as active ingredients. The composition of claim 1, wherein the hyperlipidemia is hypercholesterolemia, hypertriglyceridemia, or low density lipoprotein cholesterolemia. Atherosclerosis, coronary artery disease, ischemic stroke, or the composition for preventing limb necrosis due to lack of blood supply, which comprises Myeongil Leaf and Turmeric as active ingredients. The composition according to any one of claims 1 to 3, wherein the bright leaf and turmeric are included in a weight ratio in the range of 10: 1-1:10. The method according to any one of claims 1 to 3, wherein the light leaf and turmeric are each independently a powder of the drug itself, a dry powder of the drug, or water, C ₁ -C ₄ alcohol, ethyl acetate, and combinations thereof Composition as an extract of a solvent selected from the group consisting of. 6. The composition of claim 5 wherein the solvent is ethanol. A pharmaceutical product comprising the composition according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier or additive. 8. A pharmaceutical product according to claim 7, which is in the form of a powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, extract, injection, transdermal or suppository. 8. The pharmaceutical product according to claim 7, wherein the single leaf and turmeric are administered simultaneously or sequentially. A dietary supplement comprising the composition according to any one of claims 1 to 3 and a food acceptable carrier or additive. The dietary supplement according to claim 10, which is in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, extract, tea, jelly, or beverage. The dietary supplement according to claim 10, wherein the daily and turmeric are administered simultaneously or sequentially.

Images